Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationDepreciation & Amortization (IS)EBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetShares Repurchased
Ratios

Xeris Biopharma Holdings (XERS) Long-Term Debt Issuances (2020 - 2024)

Xeris Biopharma Holdings' Long-Term Debt Issuances history spans 3 years, with the latest figure at $50.0 million for Q1 2024.

  • For the quarter ending Q1 2024, Long-Term Debt Issuances changed N/A year-over-year to $50.0 million, compared with a TTM value of $50.0 million through Dec 2024, changed N/A, and an annual FY2024 reading of $50.0 million, changed N/A over the prior year.
  • Long-Term Debt Issuances for Q1 2024 was $50.0 million at Xeris Biopharma Holdings, up from -$97.3 million in the prior quarter.
  • The five-year high for Long-Term Debt Issuances was $97.3 million in Q1 2022, with the low at -$97.3 million in Q4 2022.
  • Average Long-Term Debt Issuances over 3 years is $13.4 million, with a median of $26.8 million recorded in 2020.